$3.56
1.66% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US9186401033
Symbol
VCNX
Sector
Industry

Vaccinex, Inc. Stock price

$3.56
+0.18 5.33% 1M
-1.84 34.07% 6M
-5.75 61.75% YTD
-8.53 70.54% 1Y
-345.04 98.98% 3Y
-1,014.94 99.65% 5Y
-2,386.24 99.85% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.06 1.66%
ISIN
US9186401033
Symbol
VCNX
Sector
Industry

Key metrics

Market capitalization $9.26m
Enterprise Value $7.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.33
P/S ratio (TTM) P/S ratio 23.74
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -51.19%
Revenue (TTM) Revenue $390.00k
EBIT (operating result TTM) EBIT $-20.34m
Free Cash Flow (TTM) Free Cash Flow $-15.87m
Cash position $2.91m
EPS (TTM) EPS $-12.58
Short interest 6.25%
Show more

Is Vaccinex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Vaccinex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Vaccinex, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Vaccinex, Inc. forecast:

Buy
100%

Financial data from Vaccinex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.39 0.39
51% 51%
100%
- Direct Costs 0.10 0.10
29% 29%
26%
0.29 0.29
56% 56%
74%
- Selling and Administrative Expenses 6.85 6.85
2% 2%
1,756%
- Research and Development Expense 14 14
19% 19%
3,505%
-20 -20
12% 12%
-5,187%
- Depreciation and Amortization 0.10 0.10
29% 29%
26%
EBIT (Operating Income) EBIT -20 -20
12% 12%
-5,214%
Net Profit -19 -19
16% 16%
-4,764%

In millions USD.

Don't miss a Thing! We will send you all news about Vaccinex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaccinex, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the...
Neutral
GlobeNewsWire
19 days ago
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Neutral
GlobeNewsWire
21 days ago
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer.
More Vaccinex, Inc. News

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Head office United States
CEO Maurice Zauderer
Employees 40
Founded 1997
Website www.vaccinex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today